Mechanism of Action of PDE5 Inhibitors in LUTS and ED: the NO-cGMP Pathway

European Urology

Volumn 55, Issue 1, 2009, Pages 49-51

  Giuliano, François ^a  

^a RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC GMP; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; VARDENAFIL;

ATHEROSCLEROSIS; BLADDER NECK; DISEASE ASSOCIATION; DRUG MECHANISM; EDITORIAL; ENZYME ACTIVATION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; LOWER URINARY TRACT SYMPTOM; NEUROMODULATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; URETHRA;

CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ERECTILE DYSFUNCTION; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PROSTATISM;

EID: 56349085887     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.10.007     Document Type: Editorial

References (12)

1. Hedlund P., Ekstrom P., Larsson B., Alm P., and Andersson K.E. Heme oxygenase and NO-synthase in the human prostate-relation to adrenergic, cholinergic and peptide-containing nerves. J Auton Nerv Syst 63 (1997) 115-126
2. Andersson K.E., and Persson K. Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology. Scand J Urol Nephrol 175 Suppl (1995) 43-53
3. Smet P.J., Jonavicius J., Marshall V.R., and de Vente J. Distribution of nitric oxide synthase-immunoreactive nerves and identification of the cellular targets of nitric oxide in guinea-pig and human urinary bladder by cGMP immunohistochemistry. Neuroscience 71 (1996) 337-348
4. Tinel H., Stelte-Ludwig B., Hutter J., and Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 98 (2006) 1259-1263
5. Persson K., Igawa Y., Mattiasson A., and Andersson K.E. Effects of inhibition of the L-arginine/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro. Br J Pharmacol 107 (1992) 178-184
6. Pandita R.K., Mizusawa H., and Andersson K.E. Intravesical oxyhemoglobin initiates bladder overactivity in conscious, normal rats. J Urol 164 (2000) 545-550
7. Burnett A.L., Calvin D.C., Chamness S.L., et al. Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. Nat Med 3 (1997) 571-574
8. Persson K., Pandita R.K., Aszodi A., et al. Functional characteristics of urinary tract smooth muscles in mice lacking cGMP protein kinase type I. Am J Physiol Regul Integr Comp Physiol 279 (2000) R1112-R1120
9. Cook A.L., and Haynes J.M. Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal 16 (2004) 253-261
10. Köhler T.S., and McVary K.T. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 55 (2009) 38-48
11. Costabile R.A., and Steers W.D. How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia?. J Sex Med 3 (2006) 676-681
12. Oger S, Behr-Roussel D, Gorny D, et al. Combination of doxazosin and sildenafil exerts an additive relaxing effect compared to each compound alone on human cavernosal and prostatic tissue. J Sex Med. In press.